Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14.

Abstract

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

Keywords: Essential thrombocythemia; Phase II study; Polycythemia vera; Vorinostat; Ykl-40.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adipokines / blood*
  • Adult
  • Aged
  • Aged, 80 and over
  • C-Reactive Protein / analysis
  • Chitinase-3-Like Protein 1
  • Female
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Hydroxamic Acids / adverse effects
  • Hydroxamic Acids / therapeutic use*
  • Lectins / blood*
  • Male
  • Middle Aged
  • Polycythemia Vera / blood
  • Polycythemia Vera / drug therapy*
  • Thrombocythemia, Essential / blood
  • Thrombocythemia, Essential / drug therapy*
  • Vorinostat

Substances

  • Adipokines
  • CHI3L1 protein, human
  • Chitinase-3-Like Protein 1
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Lectins
  • Vorinostat
  • C-Reactive Protein